Drug Approval | April 26, 2022
DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Covaxin was earlier approved for children 12-18 years of age
Covaxin was earlier approved for children 12-18 years of age
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Strive to empower public health with disinfection robotics solutions in post-pandemic era
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
Subscribe To Our Newsletter & Stay Updated
